Scientists in Australia have identified a previously unknown mechanism by which the body regulates stored sugar, a discovery that could reshape fundamental understanding of metabolism and open new avenues for treating conditions like diabetes and obesity. The research, published in the journal Nature, reveals that ubiquitin—a molecule best known for tagging damaged proteins for destruction—can also bind directly to glycogen, the body’s primary storage form of glucose, thereby influencing its breakdown.
This finding challenges long-held assumptions in biochemistry, where glycogen regulation was thought to occur primarily through enzymatic pathways involving hormones like insulin and glucagon. According to the study, ubiquitin acts as a direct regulator of glycogen degradation, particularly during fasting periods when energy demands rise and stored glucose must be mobilized.
Professor David Komander, a lead researcher on the project based in Sydney, emphasized the significance of the discovery. “It is very likely that biology textbooks will require to be revised as a result of our findings,” he stated in a press release accompanying the study. He added that the work suggests “a second pathway through which glycogen can be directly regulated—likely in response to physiological demand.”
The research team developed a novel method to visualize the ubiquitin-glycogen interaction in both animal models and human cells. In mice, they observed that glycogen carried more ubiquitin tags during fasting, coinciding with declining glycogen levels. This correlation suggests that ubiquitin tagging is not merely incidental but actively involved in signaling glycogen breakdown when the body needs to access stored energy.
These insights could have broad implications for metabolic health. Excessive glycogen accumulation is linked to a range of disorders, including type 2 diabetes, non-alcoholic fatty liver disease, and certain cardiomyopathies. By revealing a new regulatory node in glucose homeostasis, the study opens possibilities for therapies that target this ubiquitin-glycogen axis to reduce pathological sugar buildup at its source.
The study’s authors note that while the findings are promising, further research is needed to determine how this pathway functions in humans under various metabolic conditions and whether it can be safely modulated for therapeutic benefit. They also highlight the importance of understanding how this mechanism interacts with established hormonal controls to maintain overall glucose balance.
As the scientific community digests these results, the discovery underscores how even well-studied biological processes can still harbor hidden layers of regulation. For now, the focus remains on validating the mechanism in broader contexts and exploring its potential to inform future treatments for metabolic disease.